Dante Labs adds Non Invasive Prenatal Test (NIPT) to its collection of advanced genetic tests.
Today international biotech company Dante Labs introduced its Non-Invasive Prenatal Test (NIPT) based on Next Generation Sequencing (NGS) technology. Dante Labs NIPT provides a fast and accurate screen for the most common prenatal chromosomal abnormalities.
Expecting mothers will be spared an invasive procedure thanks to the increased sensitivity and reliability of Dante Labs NIPT.
Conventional prenatal testing for fetal chromosomal abnormality has involved either chorionic villus sampling or amniocentesis - both procedures are highly invasive and carry an elevated risk of miscarriage.
Dante Labs NIPT is completely safe for both mother and child and carries 0% risk of miscarriage.
The NIPT is priced at €499 on Dante Labs website.
With a turnaround time of one week, this fast and accurate non-invasive test screens for the most common fetal abnormalities related to chromosomes 13, 18, 21, X, and Y. Specifically, Dante Labs NIPT is based on the in vitro diagnostic test Illumina VeriSeq™ NIPT Solution and screens for the following diseases:
- Down Syndrome-Trisomy 21
- Edwards Syndrome-Trisomy 18
- Patau Syndrome-Trisomy 13
- Klinefelter Syndrome-XXY
- Jacobs Syndrome-XYY
- Turner Syndrome-Monosomy X
- Triple X Syndrome-XXX
- Optional reporting on fetal gender (from week 12)
The sequencing is performed at a laboratory with CLIA, CAP and ISO certifications, located in the European Union.
The test is being marketed to both physicians and consumers. Individuals should talk with their gynaecologists about the test and should always get their blood drawn by a physician's office or lab. "The demand for NIPT came from our customers," says Dante Labs CEO Andrea Riposati. "We established our first partnerships with hospitals and physicians, and they kept asking us to add a NIPT to our collection of advanced Next Generation Sequencing (NGS) DNA tests. This test will provide much greater reassurance and comfort during pregnancy."
If more than two copies of chromosome 21, 18, or 13 are found in the fetus, the pregnant woman will be referred to the classic invasive procedure to confirm the result. The present procedure for further follow-up therefore remains unchanged. Clear and informative counselling about various options after prenatal screening is of the utmost importance to support expecting couples in their decision-making process.